Clinical Trial ResultsThe Phase 2 AURORA study did not show significant improvements in light tolerance due to a greater-than-expected placebo response.
Investor SentimentShort interest is relatively high at 9.5% of the float, indicating some investor skepticism.
Risk AssessmentRisks include mixed or negative clinical data, safety concerns for clinical programs, and financing issues.